Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer
Women with epithelial ovarian cancer (EOC) are usually treated with platinum/taxane therapy after cytoreductive surgery but there is considerable inter-individual variation in response. To identify germline single-nucleotide polymorphisms (SNPs) that contribute to variations in individual responses...
Similar Items
-
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
by: Lambrechts, Sandrina, et al.
Published: (2015) -
The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis
by: Kasper Ingerslev, et al.
Published: (2017-05-01) -
Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy
by: Chenevix-Trench, Georgia, et al.
Published: (2012) -
UMP, PSIP muafakat perkasakan agenda kesukarelawanan
by: UMP, .
Published: (2010) -
Role of PSIP1/LEDGF/p75 in Lentiviral Infectivity and Integration Targeting
by: Marshall, Heather M., et al.
Published: (2007)